Related Experiment Video

Updated: Aug 26, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.2K

Adenosine signaling: Optimal target for gastric cancer immunotherapy

Junqing Wang1, Linyong Du2, Xiangjian Chen1

  • 1School of the 1St Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China.

Frontiers in Immunology
|October 3, 2022
PubMed

Insights

The adenosinergic pathway is crucial in gastric cancer (GC) development. Targeting this pathway offers a promising therapeutic strategy for advanced gastric cancer patients, improving upon current immune checkpoint inhibitor limitations.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Gastric cancer (GC) is a leading cause of cancer deaths globally.
  • Late diagnosis due to nonspecific symptoms limits treatment options for advanced gastric cancer (AGC).
  • Current immune checkpoint inhibitors (ICIs) show limited efficacy as monotherapy for AGC.

Purpose of the Study:

  • To identify novel therapeutic targets for gastric cancer.
  • To investigate the role of immune checkpoint-related genes in GC.
  • To explore the potential of the adenosinergic pathway in GC treatment.

Main Methods:

  • Analysis of expression profiles and prognostic value of 20 immune checkpoint-related genes using the Gene Expression Profiling Interactive Analysis (GEPIA) database.
  • Review of the pathophysiological functions of the adenosinergic pathway in cancer.

Main Results:

  • The adenosinergic pathway was identified as a key player in GC occurrence and development.
  • Extracellular adenosine accumulation was found to suppress immune effector cells and promote GC cell proliferation and migration.
  • Limited clinical benefit of current ICIs in AGC monotherapy necessitates alternative strategies.

Conclusions:

  • The adenosinergic pathway is a critical target for gastric cancer therapy.
  • Targeting the adenosinergic pathway presents a promising clinical application for AGC patients.
  • Further research into adenosinergic-targeting therapies could overcome limitations of existing treatments.
Keywords:
CD39CD73adenosinegastric cancerimmunotherapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

742
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

978

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
492
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K